John Magee - Flexion Therapeutics Vice President - Sales
President
Mr. John Magee serves as Vice President Sales of the Company since 2016.
Tenure | 8 years |
Professional Marks | MBA |
Phone | 781 305-7777 |
Web | www.flexiontherapeutics.com |
Flexion Therapeutics Management Efficiency
The company has return on total asset (ROA) of (18.99) % which means that it has lost $18.99 on every $100 spent on assets. This is way below average. Flexion Therapeutics' management efficiency ratios could be used to measure how well Flexion Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 228.9 M in liabilities. Flexion Therapeutics has a current ratio of 4.52, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Flexion Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Flexion Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Flexion Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Flexion to invest in growth at high rates of return. When we think about Flexion Therapeutics' use of debt, we should always consider it together with cash and equity.
Similar Executives
Showing other executives | PRESIDENT Age | ||
Mario Wijker | Teleflex Incorporated | 52 | |
Marco Molinari | HNI Corp | 55 | |
Amy Ables | Alphatec Holdings | N/A | |
Jeffrey Lorenger | HNI Corp | 58 | |
Julie Abramowski | HNI Corp | 48 | |
Mark Ojeda | Alphatec Holdings | N/A | |
Mark Nason | Skechers USA | 62 | |
Michael Greenberg | Skechers USA | 61 | |
James Ferguson | Teleflex Incorporated | N/A | |
James Leyden | Teleflex Incorporated | 52 | |
Matthew McGough | HNI Corp | N/A | |
Roger Graham | Teleflex Incorporated | N/A | |
Phillip Paccione | Skechers USA | 55 | |
Philip Paccione | Skechers USA | 62 | |
Jeffrey Black | Alphatec Holdings | 48 | |
Andrew Lukowiak | Talis Biomedical Corp | 52 | |
Karen Boylan | Teleflex Incorporated | 47 | |
Jason Hagedorn | HNI Corp | 50 | |
Jon Allen | Alphatec Holdings | N/A | |
Donna Meade | HNI Corp | 55 | |
David Sponsel | Alphatec Holdings | 45 |
Management Performance
Return On Asset | -18.99 |
Flexion Therapeutics Leadership Team
Elected by the shareholders, the Flexion Therapeutics' board of directors comprises two types of representatives: Flexion Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Flexion. The board's role is to monitor Flexion Therapeutics' management team and ensure that shareholders' interests are well served. Flexion Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Flexion Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
David Arkowitz, CFO, Principal Financial Officer and Principal Accounting Officer | ||
Sandesh Mahatme, Director | ||
Scott Canute, Director | ||
Mark Levine, Senior Vice President General Counsel, Secretary | ||
Kerry Wentworth, Chief Regulatory Officer | ||
Dan Thornton, Vice President - Market Access | ||
John Magee, Vice President - Sales | ||
Neil Bodick, Chief Medical Officer & Co-Founder | ||
Mark Fraga, Vice President - Marketing | ||
Michael Clayman, CEO, Co-Founder, Board Member | ||
Ann Merrifield, Director | ||
Alan Milinazzo, Independent Director | ||
Jon Mahlowitz, VP of Legal Affairs | ||
Frederick Driscoll, CFO and Principal Accounting Officer | ||
Heath Lukatch, Independent Director | ||
Christina Willwerth, Chief Strategy Officer | ||
Patrick Mahaffy, Chairman of the Board | ||
Samuel Colella, Independent Director | ||
Yamo Deniz, Chief Medical Officer | ||
Mark Stejbach, Director | ||
Scott Kelley, Vice President - Medical Affairs |
Flexion Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Flexion Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Asset | -18.99 | |||
Profit Margin | (92.52) % | |||
Operating Margin | (71.24) % | |||
Current Valuation | 408.79 M | |||
Shares Outstanding | 49.94 M | |||
Shares Owned By Insiders | 3.58 % | |||
Shares Owned By Institutions | 92.20 % | |||
Number Of Shares Shorted | 5.67 M | |||
Price To Earning | (8.29) X | |||
Price To Book | 35.88 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Flexion Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Flexion Therapeutics' short interest history, or implied volatility extrapolated from Flexion Therapeutics options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Other Consideration for investing in Flexion Stock
If you are still planning to invest in Flexion Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Flexion Therapeutics' history and understand the potential risks before investing.
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Content Syndication Quickly integrate customizable finance content to your own investment portal |